Skip to main content

Podcast

Happy Diwali (11.1.2024)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Blue Collar Arthritis (10.25.2024)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com Register now for RheumNow.live 2025

EMJ Podcast Interview With Dr. Jack Cush

This week, Jonathan is joined by John J Cush, from Dallas, Texas, USA. The two doctors explore novel treatment avenues for rheumatic diseases, and discuss the exciting potential of AI and telemedicine.

ANA+ Consult (10.18.2024)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Dot The I, Cross The T (10.11.2024)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Todays reports suggest where to look for help, especially with regard to pain.

Stop Counting Bugs (10.4.2024)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com -- This weeks rants include the microbiome, PsA treatment choices and fishing for P-values in research.

RA Risk Radar: Heart Disease, Infection, and Malignancy Sponsored by AbbVie Medical Affairs

Rheumatologists Dr. Jeffrey Curtis and Dr. Jon Giles discuss the risk of comorbidities that can occur as a consequence of uncontrolled inflammation in RA

I Cant Treat Ugly (9.20.2024)

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Systemic Sclerosis Insights (9.13.2024)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Linger On The Fingers (9.6.2024)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.

Earlier treatment with biologics to reduce the risk of organ damage

Sponsored by GSK US Medical Affairs Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.
×